

SUPPLEMENTARY FIGURE LEGENDS

Figure S1. CONSORT diagram.

Figure S2. Patient and physician reported functional outcomes after 5-day preoperative RT and surgery. (A) Physician-reported Musculoskeletal Tumor Society Score at baseline and 12, 18 and/or 24 months after enrollment. Individual patient trends shown in top panel; average values at each time point shown in bottom panel. (B) Patient-reported Toronto Extremity Salvage Score at baseline and 12, 18 and/or 24 months after enrollment. Individual patient trends shown in top panel; average values at each time point shown in bottom panel.

Figure S3. Distribution of soft tissue sarcoma histologic subtypes among patients enrolled on the five-day neoadjuvant RT phase 2 study. *Abbr.: UPS = undifferentiated pleomorphic sarcoma, NOS = not otherwise specified, MFS = myxofibrosarcoma, MPNST = malignant peripheral nerve sheath tumor, RMS = rhabdomyosarcoma, WDLS = well-differentiated liposarcoma.*

Figure S4. Characteristics of major wound complications. (A) Frequency of wound complications according to superficial versus deep tumor location, and by tumor size. (B) Time interval (days) from the end of neoadjuvant RT to surgery in patients who developed major wound complications and those who did not. (C) Radiation dose (Gy) to 0.5-cc volume of skin in patients who developed major wound complications and those who did not. (D) Volume of skin (cc) receiving at least 12 Gy of radiation in patients who developed major wound complications and those who did not.